10 articles with Insilico Biotechnology
Insilico and Janssen take another step towards predictive biomanufacturing: Digital Twins allow for accelerated timelines in cell line development for biologics production
Insilico Biotechnology AG and the Janssen Pharmaceutical Companies of Johnson & Johnson announced an agreement to apply Insilico's predictive Digital Twins for the early selection of high-performing cells to further boost efficiency and throughput of their cell line development workflow.
Insilico Biotechnology AG and the Laboratory of Systems Theory and Automatic Control at the Institute for Automation Engineering of the Otto von Guericke University Magdeburg started a joint project on model predictive control for the production of monoclonal antibodies in mammalian cell culture processes using Insilico's Digital Twins.
Insilico launches comprehensive portfolio of predictive Digital Twins for cell culture process development
Insilico Biotechnology AG offers a suite of Digital Twins that delivers high quality predictions for accelerating product time to market.
Insilico Biotechnology AG announces the opening of a representation in Singapore to develop its business in the Asia-Pacific (APAC) region and to strengthen support for its growing customer base.
Insilico and Teva enter collaboration to apply predictive Digital Twins for biopharmaceutical production
Insilico Biotechnology AG and Teva Pharmaceutical Industries Ltd. announced an agreement to apply Insilico’s technology for predictive biomanufacturing to create and implement more efficient production processes of Teva’s biopharmaceutical therapeutics.
As 2019 gets underway for the biopharma industry, more companies are increasing their reliance on the use of artificial intelligence as part of their drug discovery process.
Scientists call it the "linchpin of energy metabolism".
Sensyne Health, a London-based healthcare artificial intelligence (AI) company founded by biotech entrepreneur Paul Drayson, recently launched an initial public offering (IPO) on the London AIM market. Drayson’s plan is to raise $78 million. It’s just one of many companies that are exploiting adv...
Buck Institute, Insilico Med and Juvenescence Found Napa Therapeutics to Focus on Age-Related Dis...
8/16/2018Yet another company is launched to focus on longevity and diseases of aging. The Buck Institute for Research on Aging, Insilico Medicine, an artificial intelligence (AI) company with offices and resources in the U.S., Belgium, Russia, the UK, Taiwan and Korea, and Juvenescence, also a human longe...
For many companies, artificial intelligence has become a key tool in drug development. Now, two companies that specialize in AI-backed drug development are teaming up to take on the rare disease known as Duchene Muscular Dystrophy.